BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
BeiGene, Ltd. - American Depositary Shares (BGNE)
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beigene.com/phoenix.zhtml?c=254246&p=irol-irhome_pf
Company Research
Source: Business Wire
5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with the broadest label of any BTK inhibitorAt a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a next-generation BCL2 inhibitor, in combination with BRUKINSA highlighting the potential of this fixed-duration, oral-only combination as a best-in-disease optionData for BTK degrader BGB-16673 from phase 1/2 study highlight its potential in both treatment-resistant CLL and other B-cell malignancies representing high unmet needs SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company
Show less
Read more
Impact Snapshot
Event Time:
BGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BGNE alerts
High impacting BeiGene, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BGNE
News
- TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy [Yahoo! Finance]Yahoo! Finance
- TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyBusiness Wire
- With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns [Yahoo! Finance]Yahoo! Finance
- BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- BeiGene Announces Global Licensing Agreement for MAT2A InhibitorBusiness Wire
BGNE
Earnings
- 11/12/24 - Miss
BGNE
Sec Filings
- 12/23/24 - Form 8-K
- 12/17/24 - Form 4
- 12/12/24 - Form 4
- BGNE's page on the SEC website